{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+matched+placebo&page=2",
    "query": {
      "intervention": "Dapagliflozin matched placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 52,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+matched+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+matched+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T19:24:25.487Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03782259",
      "title": "Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Myocardial Fibrosis",
        "Myocardial Inflammation"
      ],
      "interventions": [
        {
          "name": "dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2019-02-26",
      "completion_date": "2022-11-16",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782259"
    },
    {
      "nct_id": "NCT03316131",
      "title": "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asymptomatic Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Verinurad",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matched placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-10-25",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316131"
    },
    {
      "nct_id": "NCT02547935",
      "title": "A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus, CKD and Albuminuria"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 459,
      "start_date": "2015-09-21",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 37,
      "location_summary": "Peoria, Arizona • Chula Vista, California • Concord, California + 34 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02547935"
    },
    {
      "nct_id": "NCT01031680",
      "title": "Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Cardiovascular Disease",
        "Hypertension",
        "Inadequate Glycaemic Control"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 922,
      "start_date": "2010-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2013-10-29",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 60,
      "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031680"
    },
    {
      "nct_id": "NCT04492722",
      "title": "A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "AZD5718",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 613,
      "start_date": "2020-10-01",
      "completion_date": "2022-09-06",
      "has_results": true,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 22,
      "location_summary": "Canoga Park, California • La Mesa, California • San Carlos, California + 19 more",
      "locations": [
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492722"
    },
    {
      "nct_id": "NCT01619059",
      "title": "Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2012-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619059"
    },
    {
      "nct_id": "NCT02653482",
      "title": "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Systolic Function"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Luke's Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "119 Years",
        "sex": "ALL",
        "summary": "19 Years to 119 Years"
      },
      "enrollment_count": 263,
      "start_date": "2016-03-03",
      "completion_date": "2019-06-28",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 25,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653482"
    },
    {
      "nct_id": "NCT05570305",
      "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Zibotentan",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin and Zibotentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Medical Center Groningen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-10-06",
      "completion_date": "2025-03-05",
      "has_results": false,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570305"
    },
    {
      "nct_id": "NCT03036124",
      "title": "Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 4744,
      "start_date": "2017-02-08",
      "completion_date": "2019-07-17",
      "has_results": true,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 86,
      "location_summary": "Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036124"
    },
    {
      "nct_id": "NCT00683878",
      "title": "Add-on to Thiazolidinedione (TZD) Failures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinedione (Pioglitazone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 972,
      "start_date": "2008-07",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-04T19:24:25.487Z",
      "location_count": 57,
      "location_summary": "Anniston, Alabama • Ozark, Alabama • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00683878"
    }
  ]
}